Richard Klausner
CIK 1591178 · Executive Chairman · last filed 2026-06-12
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$6.88M
Companies
4
Total Filings
56
Lifetime Open-Market Net
-$11.02M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| LYEL | Director | 190,557 | $12.99 | $2.48M | -$108.4K | 10 | 2026-06-12 |
| PBLS | Director | — | — | — | $0 | 1 | 2026-06-11 |
| Juno Therapeutics, Inc. (JUNO) Delisted | Director | 0 | — | — | -$10.49M | 27 | 2018-03-07 |
| ILMN | Sr VP, Chief Medical Officer | 22,847 | $192.98 | $4.41M | -$420.0K | 10 | 2016-02-01 |
Recent Filings · Page 2 of 6
56 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2023-08-15 | LYEL | Notice (144) | −4,485 | -$10.3K | EDGAR |
| 2023-07-17 | LYEL | Notice (144) | −14,500 | -$42.0K | EDGAR |
| 2023-07-17 | LYEL | Notice (144) | −3,300 | -$9.6K | EDGAR |
| 2023-07-17 | LYEL | Notice (144) | −3,300 | -$9.6K | EDGAR |
| 2023-07-17 | LYEL | Notice (144) | −3,300 | -$9.6K | EDGAR |
| 2023-06-20 | LYEL | Grant (A) | — | $0 | EDGAR |
| 2022-09-27 | LYEL | Sell (S) | −11,100 | -$71.0K | EDGAR |
| 2022-06-10 | LYEL | Grant (A) | — | $0 | EDGAR |
| 2021-06-23 | LYEL | Conv (C) | +3,765,842 | $0 | EDGAR |
| 2018-03-07 | Juno Therapeutics, Inc. (JUNO) Delisted | Mixed | −728,775 | -$61.38M | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.